An ongoing series to help providers set the foundations of a patient's care.
FDA Approves Doravirine (Pifeltro) and New FDC With TDF/3TC (Delstrigo) in the U.S.
More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best
Who Tends to Gain Weight With HIV Treatment?
The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.
Which Hepatitis C Treatment to Start
New Professional Resources for Providers to Address HIV/HCV Coinfection
Prison Health Is Public Health: The Case for Testing and Treating Hepatitis C in Prisons
Too Few Teens and Youth Adults Using Opioids Are Screened for Hepatitis C and HIV, New Study Finds
De-Simplifying Single-Tablet Regimens for HIV Treatment
This Week in HIV Research: Rethinking PrEP Guidelines
Chlamydia and Gonorrhea Responsible for 10% of New HIV Infections Among MSM, According to New Study
This Week in HIV Research: Don't Assume PrEP Use Increases STI Rates
Virginia Governor Northam's Blackface Med School Antics Are the Reason Black Doctors Matter
This Week in HIV Research: The Power of 10,000 Steps
For Our Stable HIV Patients, Why Are We Still Sending All These Lab Tests So Often?
Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review
NHS England Doubles Places on IMPACT PrEP Study to 26,000
'Female Condom' Gets a Genderless Rebrand From FDA
New Professional Resources for Providers to Address HIV/HCV Coinfection
This Week in HIV Research: Check Your Frailty
Six Things Providers Should Know About HIV-Associated Neurocognitive Disorders
Pharma Payments to Doctors Associated With Spike in Opioid Deaths; Implications for HIV Epidemic
This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide
'Female Condom' Gets a Genderless Rebrand From FDA
Virginia Governor Northam's Blackface Med School Antics Are the Reason Black Doctors Matter
Chlamydia and Gonorrhea Responsible for 10% of New HIV Infections Among MSM, According to New Study
For Our Stable HIV Patients, Why Are We Still Sending All These Lab Tests So Often?
Six Things Providers Should Know About HIV-Associated Neurocognitive Disorders
This Week in HIV Research: Check Your Frailty
This Week in HIV Research: The Power of 10,000 Steps
New Professional Resources for Providers to Address HIV/HCV Coinfection
© 2019 Remedy Health Media, LLC. All Rights Reserved
TheBodyPRO: About TheBodyPRO | Contact TheBodyPRO | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBodyPRO and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
